Neupulse, a UK-based neurotherapeutics company, has raised £3 million in new funding to accelerate the development and commercialisation of its non-drug therapy for Tourette Syndrome.

The round was led by Eos Advisory and the Midlands Engine Investment Fund II, through appointed fund manager Mercia Ventures, with participation from existing and new investors. The funding will support product development, regulatory progress, and early commercialisation to ensure the technology reaches individuals who need it most.

The investment comes at a time when venture and growth funding remains highly constrained, highlighting the strength of Neupulse’s proposition and investor confidence in the company’s mission and execution. The new capital will enable Neupulse to move decisively from development towards a commercial launch in mid-2026 while continuing to build the evidence base required by clinicians, regulators, and healthcare systems.

Neupulse first secured funding from the Midlands Engine Investment Fund II in 2024 to finalise development of a non-drug treatment to help manage the symptoms of Tourette Syndrome. The initial £500,000 investment supported continued research into the therapy wristband device and clinical trials.

Eos and Mercia Ventures bring not only capital but strategic expertise to support Neupulse’s growth. Their continued leadership reflects a shared belief in the company’s long-term potential and its ability to generate both commercial and clinical value.

Paul Cable, CEO of Neupulse, said: “This investment underlines the unmet need in providing people with conditions like Tourette Syndrome a solution to manage their condition, and as a company, we are driven to improve the lives of individuals with these conditions.”

Ian Rhodes, chair of the board at Neupulse, added: “This is a great example of advanced biomedical research from a leading UK university creating an initial UK market launch during 2026. This will increasingly benefit the UK economy as the technology scales out globally.”

David Tindall, senior investment manager at the British Business Bank, said: “Neupulse’s growth over the past year, following investment from the Midlands Engine Investment Fund II, has been impressive. By addressing a clear gap in the market and delivering a much-needed solution for those affected, the business exemplifies the fund’s commitment to backing ambitious, high-growth companies. This latest round of funding will further support Neupulse in developing and launching new treatment options.”

Andrew McNeill, investor director at Eos, added: “We are delighted to support the next chapter of Neupulse as they move towards commercialisation. This is exactly the kind of company and science we like to back — passionate founders and technology with the potential to positively impact the lives of people across the globe.”

Sandy Reid, fund principal at Mercia Ventures, said: “Tourette Syndrome is believed to affect up to two per cent of all children worldwide but currently the only treatments are medication and behavioural therapy, neither of which are ideal solutions. Neupulse’s device offers a genuine alternative that could transform lives.”

The Midlands Engine Investment Fund II covers the entire Midlands region and provides debt finance from twenty-five thousand pounds to two million pounds and equity investment up to five million pounds. Its purpose is to drive sustainable economic growth by supporting innovation and creating local opportunity for new and growing businesses. The fund increases the supply and diversity of early-stage finance for smaller businesses, providing funds to firms that might otherwise not receive investment and helping to break down barriers to access finance.